Abstract

Background: Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) that is indicated for the treatment of moderate to severe atopic dermatitis (AD). Since its approval in 2017, several cases have been described of new-onset psoriasis after starting Dupilumab for AD. With psoriasis being thought of as a primarily Th1-driven inflammatory process, theories have postulated that Dupilumab shifts the T-helper cell response from a Th2 to a Th1-mediated inflammatory response inducing psoriasis in these patients. Despite these theories and reported cases, in our literature review, we were unable to find any cases of psoriatic alopecia following the initiation of Dupilumab. Methods: A retrospective chart review of one patient with biopsy-confirmed psoriatic alopecia following the initiation of Dupilumab. Results: In our literature review, we found 13 cases of new-onset psoriasis following the initiation of Dupilumab. To our knowledge, we present the first case of psoriatic alopecia arising in a 40-year-old female after starting treatment with Dupilumab. Conclusion: This case raises the concern of psoriatic alopecia as a possible side-effect of Dupilumab. We aim to describe this case and investigate the relationship between Dupilumab and psoriatic alopecia.

Financial Disclosure:
No current or relevant financial relationships exist.